Two-dose COVID-19 vaccination regimens do not elicit adequate neutralising antibodies against the Omicron coronavirus variant, according to British researchers, implying that higher infections in persons who have been infected or vaccinated are expected. On Monday, researchers from the University of Oxford revealed the findings of an unpublished investigation in which they analysed blood samples from participants in a big trial who were given dosages from AstraZeneca-Oxford or Pfizer-BioNTech.
The findings came only one day after British Prime Minister Boris Johnson warned that two vaccination doses would not be enough to prevent the Omicron form from spreading.
